Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $549.31 | 21 | 84.6% |
| Education | $99.99 | 1 | 15.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $262.44 | 10 | $0 (2023) |
| Janssen Biotech, Inc. | $132.66 | 2 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $82.92 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $47.35 | 2 | $0 (2023) |
| GENZYME CORPORATION | $41.98 | 2 | $0 (2022) |
| Galderma Laboratories, L.P. | $31.02 | 2 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.80 | 1 | $0 (2024) |
| Amgen Inc. | $16.97 | 1 | $0 (2021) |
| MAYNE PHARMA INC. | $12.16 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21.80 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21.80) |
| 2023 | $247.02 | 6 | ABBVIE INC. ($133.20) |
| 2022 | $148.63 | 7 | ABBVIE INC. ($114.05) |
| 2021 | $231.85 | 8 | Janssen Biotech, Inc. ($132.66) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | CYLTEZO (Biological) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: CNS | ||||||
| 11/03/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.25 | General |
| Category: IMMUNOLOGY | ||||||
| 09/07/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $82.92 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/07/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: IMMUNOLOGY | ||||||
| 04/25/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $97.67 | General |
| Category: IMMUNOLOGY | ||||||
| 04/06/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $30.90 | General |
| Category: Dermatology | ||||||
| 01/31/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: IMMUNOLOGY | ||||||
| 06/30/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: IMMUNOLOGY | ||||||
| 05/03/2022 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $16.45 | General |
| 04/13/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: IMMUNOLOGY | ||||||
| 03/23/2022 | ABBVIE INC. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: IMMUNOLOGY | ||||||
| 02/23/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: IMMUNOLOGY | ||||||
| 02/17/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: IMMUNOLOGY | ||||||
| 02/09/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Immunology | ||||||
| 11/30/2021 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: ACNE | ||||||
| 10/28/2021 | GENZYME CORPORATION | LIBTAYO (Biological), LIBTAYO | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: Oncology | ||||||
| 08/12/2021 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: IMMUNOLOGY | ||||||
| 07/14/2021 | Galderma Laboratories, L.P. | AKLIEF (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: ACNE | ||||||
| 05/06/2021 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $32.67 | General |
| Category: Immunology | ||||||
| 04/29/2021 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Inflammation | ||||||
| 02/10/2021 | MAYNE PHARMA INC. | — | Food and Beverage | In-kind items and services | $12.16 | General |
| 01/12/2021 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 693 | 1,242 | $163,127 | $51,495 |
| 2022 | 13 | 732 | 1,307 | $139,104 | $35,032 |
| 2021 | 13 | 1,561 | 3,410 | $375,478 | $109,017 |
| 2020 | 11 | 1,387 | 2,863 | $281,764 | $83,689 |
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 127 | 189 | $48,133 | $15,795 | 32.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 77 | 77 | $25,641 | $8,060 | 31.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 88 | 91 | $18,109 | $5,486 | 30.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 40 | 59 | $13,157 | $4,440 | 33.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 108 | 127 | $16,891 | $4,331 | 25.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 66 | 74 | $13,246 | $4,223 | 31.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 43 | 43 | $9,675 | $3,022 | 31.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 80 | 473 | $6,045 | $2,007 | 33.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 14 | 16 | $5,344 | $1,810 | 33.9% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 15 | 15 | $3,720 | $1,267 | 34.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 24 | 31 | $3,069 | $1,014 | 33.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 11 | 47 | $97.00 | $39.28 | 40.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 188 | 231 | $42,402 | $10,351 | 24.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 139 | 151 | $20,802 | $4,560 | 21.9% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 31 | 39 | $13,546 | $3,816 | 28.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 48 | 57 | $13,357 | $3,479 | 26.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 54 | 55 | $11,666 | $3,041 | 26.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 49 | 49 | $11,082 | $2,664 | 24.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 108 | 594 | $8,316 | $2,206 | 26.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 45 | 53 | $6,070 | $1,494 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 15 | $3,886 | $975.40 | 25.1% |
| 10060 | Simple or single drainage of skin abscess | Office | 2022 | 11 | 11 | $2,811 | $878.36 | 31.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 20 | 20 | $2,952 | $809.49 | 27.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 11 | 12 | $1,267 | $434.15 | 34.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 15 | 20 | $947.20 | $324.68 | 34.3% |
About Sarah Owen, ARNP
Sarah Owen, ARNP is a Family healthcare provider based in Oak Harbor, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2017. The National Provider Identifier (NPI) number assigned to this provider is 1154842680.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sarah Owen, ARNP has received a total of $649.30 in payments from pharmaceutical and medical device companies, with $21.80 received in 2024. These payments were reported across 22 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($549.31).
As a Medicare-enrolled provider, Owen has provided services to 4,373 Medicare beneficiaries, totaling 8,822 services with total Medicare billing of $279,233. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Practice Information
- Specialty Family
- Location Oak Harbor, WA
- Active Since 07/06/2017
- Last Updated 07/21/2022
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1154842680
Products in Payments
- SKYRIZI (Biological) $201.72
- TREMFYA (Drug) $132.66
- DUPIXENT (Biological) $101.05
- RINVOQ (Biological) $37.25
- AKLIEF (Drug) $31.02
- COSENTYX (Drug) $30.90
- LIBTAYO (Biological) $23.85
- HUMIRA (Biological) $23.47
- CYLTEZO (Biological) $21.80
- Otezla (Drug) $16.97
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Oak Harbor
Ms. Annette Fly
Family — Payments: $373.70
Eryn Beaupre, Fnp, FNP
Family — Payments: $209.26
Mrs. Amy Epp, Fnp-C, FNP-C
Family — Payments: $119.37
Amy Walchenbach, Arnp, Cfnp, ARNP, CFNP
Family — Payments: $110.00
Mrs. Amanda Moore, Fnp, FNP
Family — Payments: $83.75
Erin Aas, Arnp, ARNP
Family — Payments: $24.24